US FDA accepts filing of Roxro's intranasal ketorolac
This article was originally published in Scrip
Executive Summary
The US FDAhas accepted Roxro Pharma's NDA for its lead candidate, ROX-888 – an intranasal formulation of the NSAID ketorolac for the management of moderate-to-severe pain without the risk of addiction or the other negative effects of narcotics.